Overview Ib Study of the Efficacy and Safety of IBI310 Combined With Sintilimab in Advanced Hepatocellular Carcinoma Status: Recruiting Trial end date: 2023-04-01 Target enrollment: Participant gender: Summary An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma Phase: Phase 1 Details Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.